Skip to content
Wenlo
Sign in
← Markets

InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Inc. (INM) — Form 8-K: Current report

8-KINMFiled Nov 10, 2026, 11:45 AM ET· Period Nov 6, 2026

About this filing

InMed Pharmaceuticals Inc. (INM) filed an 8-K on Nov 10, 2026 reporting entry into a material agreement (Item 1.01), a completed acquisition or sale of assets (Item 2.01), results of operations (earnings) (Item 2.02) and 7 more items, with exhibits (Item 9.01).

View original filing on SEC.gov (opens SEC EDGAR)

Key facts

  • Item 1.01 · Entry into a material agreement
  • Item 2.01 · Completed acquisition or sale of assets
  • Item 2.02 · Results of operations (earnings)
  • Item 3.02 · Unregistered sale of shares
  • Item 3.03 · Change to shareholder rights
  • Item 5.01 · Change in control
  • Item 5.02 · Executive or director change or pay arrangement
  • Item 5.03 · Charter, bylaw or fiscal-year change
  • Item 5.05 · Code of ethics change or waiver
  • Item 5.06 · Change in shell company status
  • Item 9.01 · Financial statements and exhibits

More INM filings

Not investment advice. Summaries can contain errors; the SEC filing is the official record.